EO 14398 IDIQ: chemistry, manufacturing and controls and related services for development of drug substances (trnd 1)
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- 75N95026D00006
- Awardee
-
Curia Global Inc. UEI ELCNZCS8GEA3
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Task orders
- 0
Award facts
- Opportunity
-
- Chemistry, Manufacturing and Controls and Related Services for Development of Drug Substances Solicitation · 75N95024R00094 · Posted Oct 9, 2024
- Last date to order 5% complete
- IDV ceiling
- $49,713,679.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 11 offers Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
The National Institute on Drug Abuse awarded a multiple-award indefinite-delivery contract to Curia Global Inc. (doing business as Amri) on August 1, 2026, with a ceiling of $49,713,679 and an ultimate completion date of May 14, 2031.
The IDIQ supports chemistry, manufacturing, and controls (CMC) services for the development of drug substances intended to advance preclinical and Investigational New Drug (IND)-enabling studies. Work is performed in the United States. The contract spans three technical areas: small molecules, peptides, and biopharmaceuticals. Offerors were able to propose on one, two, or all three areas.
The originating solicitation, posted October 9, 2024 with proposals due December 3, 2024, sought to ensure receipt of drug substances of sufficient quality and quantity to support these studies. Evaluation criteria included technical approach, personnel qualifications, facilities, quality management, and organizational experience. The solicitation was unrestricted with no set-aside designations.
The period of performance runs from September 1, 2025 through May 14, 2031. The contract carries a minimum guarantee of $1,000 per IDIQ awardee.
Quick answers
Who was awarded contract 75N95026D00006?
75N95026D00006 was awarded to Curia Global Inc. by National Institute on Drug Abuse (National Institutes of Health) on August 1, 2026.
How much is contract 75N95026D00006 worth?
75N95026D00006's own ceiling is $49,713,679.
Who can order from contract 75N95026D00006?
75N95026D00006 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 75N95026D00006 competed?
The extent of competition for 75N95026D00006 was full and open competition. The government received 11 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV